Imatinib for highly chemoresistant Kaposi sarcoma in a patient with long-term HIV control: a case report and literature review

Current Oncology

W. Cao²  B. Routy³  M. Chababi-Atallah⁴  B. Lemire¹  J.P. Routy¹  K. Vyboh¹ 

[1]McGill University Health Center

[2]McGill University Health Center and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

[3]Gustave Roussy Comprehensive Cancer Center and Institut national de la santé et de la recherché médicale (inserm)

[4]Centre hospitalier universitaire de Sherbrooke

关键词: HIV-1;    Kaposi sarcoma;    imatinib;    autophagy;   

DOI  :  

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Kaposi sarcoma (ks) is a vascular tumour caused by oncogenic human herpesvirus type 8; it often occurs with hiv-associated immunosuppression. Numerous cellular signalling pathways are involved in the pathogenesis of ks, among which receptor tyrosine kinases such as the c-Kit and platelet-derived growth factor receptors play an important role. Imatinib mesylate, a tyrosine kinase inhibitor, has resulted in partial regression of ks lesions in one third of treated patients, but its mechanism of action remains unclear.Here, we report the case of a white man with recurrent ks despite well-suppressed hiv infection and multiple chemotherapies who received imatinib and showed a complete and sustained tumour response. To our knowledge, this report is the first showing the value of imatinib in the management of ks in the context of long-lasting hiv control with adequate quantitative CD4 recovery. Our case indicates that imatinib can be a treatment option for highly chemoresistant recurrent ks in patients on long-term antiretroviral therapy.

【 授权许可】

Unknown